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Background: Alzheimer’s disease (AD) is a complex, irreversible neurodegenerative disorder. At present there are
neither reliable markers to diagnose AD at an early stage nor therapy. To investigate underlying disease
mechanisms, induced pluripotent stem cells (iPSCs) allow the generation of patient-derived neuronal cells in a dish.
Results: In this study, employing iPS technology, we derived and characterized iPSCs from dermal fibroblasts of an
82-year-old female patient affected by sporadic AD. The AD-iPSCs were differentiated into neuronal cells, in order to
generate disease-specific protein association networks modeling the molecular pathology on the transcriptome
level of AD, to analyse the reflection of the disease phenotype in gene expression in AD-iPS neuronal cells, in
particular in the ubiquitin-proteasome system (UPS), and to address expression of typical AD proteins.
We detected the expression of p-tau and GSK3B, a physiological kinase of tau, in neuronal cells derived from
AD-iPSCs. Treatment of neuronal cells differentiated from AD-iPSCs with an inhibitor of γ-secretase resulted in the
down-regulation of p-tau. Transcriptome analysis of AD-iPS derived neuronal cells revealed significant changes in
the expression of genes associated with AD and with the constitutive as well as the inducible subunits of the proteasome
complex. The neuronal cells expressed numerous genes associated with sub-regions within the brain thus suggesting
the usefulness of our in-vitro model. Moreover, an AD-related protein interaction network composed of APP and GSK3B
among others could be generated using neuronal cells differentiated from two AD-iPS cell lines.
Conclusions: Our study demonstrates how an iPSC-based model system could represent (i) a tool to study the
underlying molecular basis of sporadic AD, (ii) a platform for drug screening and toxicology studies which might
unveil novel therapeutic avenues for this debilitating neuronal disorder.
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Alzheimer’s disease (AD) is characterized by histopatho-
logical changes, designated as senile plaques and fibril-
lary deposits, which ultimately lead to the death of
neuronal cells in particular in the cerebral cortex of the
brain [1,2]. The familial form of AD is rare, affecting less
than five percent of AD patients and has been associated
with mutations of Presenilin 1 (PSEN1), Presenilin 2
(PSEN2) and Amyloid Precursor Protein (APP) [3,4].
These mutations result in incorrect cleavage of the
protein, producing a deposited protein of amyloid-β
(Aβ) that is more likely to form plaques [1,5]. Little is
known about the molecular basis of multifactorial
sporadic AD. In post-mortem examination of patients
with AD, massive accumulation of two types of amyl-
oid fibril senile plaques (Aβ40, Aβ42) and hyperpho-
sphorylated tau forming paired helical filaments could
be detected [6,7]. Both types of amyloid fibrils are
mainly created enzymatically by β- and γ-secretase ac-
tivity from the APP [8].
The most widely accepted theory for the onset of spor-
adic AD is the accumulation of extracellular Aβ42 in an
aggregated state in the brain, subsequently leading to the
formation of neurofibrillary tangles (NFT) containing
hyperphosphorylated tau proteins and consequently to
its inactivation, thus leading to inhibition of binding to
the spindle apparatus and hence disrupted axonal trans-
port [9,10]. The major modification of tau is its phos-
phorylation. Its hyperphosphorylation has been shown
to be the critical step in the formation of NFTs [11,12].
One of the kinases that phosphorylates tau in-vivo is
glycogen synthase kinase-3β (GSK3B), which is widely
expressed in all tissues with elevated expression in devel-
oping brains [13]. Unlike many other kinases, GSK3B is
believed to be permanently active in resting cells and in
neurons without extracellular stimulation and can be
inactivated by Ser9 phosphorylation [14].
Moreover, the ubiquitin-proteasome system (UPS)
has been shown to be involved in the pathogenesis of
AD [15-18].
The UPS consists of the 26S proteasome and the small
protein ubiquitin, a post-translational modification, and
is operative in all eukaryotes for intracellular protein
homeostasis and quality [19,20]. The alternative form of
the constitutive proteasome is the immunoproteasome
complex [21]. It was demonstrated in in-vitro experi-
ments that the accumulation of Aβ peptide in APP/
PSEN1 mutant neuronal cell culture leads to the inhib-
ition of the proteasome as well as the de-ubiquitinating
enzymes (DUBs) [15]. Despite increasing knowledge on
AD-associated pathology, the molecular mechanisms
underlying the cause of sporadic and familial AD are still
not completely understood. This limitation is primarily
due to limited access and availability of viable neuronalcells from AD patients because of ethical and practical
reasons. Human induced pluripotent stem (iPSCs) cells
enables the generation of clinically relevant neuronal
cells in-vitro. Patient-derived skin cells are an easily ac-
cessible source for reprogramming and the obtained
neuronal cells can be used to investigate the pathogen-
esis of neuronal disorders, including Parkinson disease
and Alzheimer’s disease [22-26].
In our study, we reprogrammed dermal fibroblasts ob-
tained from an 82-year-old female patient diagnosed with
late-stage AD to iPSCs in one reprogramming experiment.
The two derived iPSC lines showed pluripotency-associated
properties similar to human embryonic stem cells (hESC)
and they could be successfully differentiated into neuronal
cells in-vitro. The differentiated neuronal cells seemed to
reflect the sporadic AD phenotype in the brain of the
patient, including the expression of p-tau proteins, the
up-regulation of GSK3B protein and its phosphorylation
in contrast to the parental dermal fibroblast cells. In
addition, numerous AD-related genes were found to be
down-regulated, as revealed by microarray-based gene ex-
pression analysis of one neuronal differentiation experi-
ment per AD-iPS cell line. Most notably these genes could
be allocated to brain regions affected by Alzheimer’s
disease.
We demonstrated a down-regulation of p-tau proteins
in AD neuronal cells with an inhibitor of γ-secretase. In
addition, neuronal cells differentiated from the patient
iPSCs showed an up-regulation of a number of neuronal
and biological processes, which include development of
the nervous system, neurogenesis, WNT signaling path-
way, the lysosome, glutathion metabolism as well as the
alanine, aspartate and glutamate metabolism. Further-
more, the down-regulation of AD-related genes enabled
us to successfully construct a protein association net-
work using the STRING database reflecting the presence
of AD-related disease mechanisms in our iPSCs model.
Finally, we could show that gene regulation of the con-
stitutive as well as of the inducible subunits of the prote-
asome complex is affected in iPSC-derived neurons from
the AD patient compared to the healthy subject. Further
investigations are needed to better understand the mo-
lecular basis of the onset and progression of Alzheimer’s
disease. Elucidating the molecular mechanism of spor-
adic AD by modeling it via iPSC technology and protein
association networks could provide valuable information
needed to uncover appropriate strategies against the
early onset of the disease.
Results
Generation and characterization of sporadic AD-iPSCs
Dermal fibroblasts were isolated from an 82-year-old
woman diagnosed with final stage AD. The cell line was
named NFH-46, and lack of AD-related mutations, such
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sequencing analysis (Additional file 1). HLA haplotype
analysis in the AD donor did not reveal any association of
HLA alleles to Morbus Alzheimer. The HLA-alleles HLA-
A*01:01,*03:01; B*08,*35, C*04:01,*07:01, DRB1*03:01,
*11:01 were found in NFH-46. However, the Alzheimer-
related HLA-alleles HLA-A*02, HLA-B*07 and HLA-
C*07:02 could not be detected.
AD-iPSCs were generated by retroviral transduction
using the classical Yamanaka cocktail [27], which in-
cludes the four transcription factors OCT4, KLF4,
SOX2, and c-MYC, as demonstrated previously [28]. In
a single reprogramming experiment several colonies
exhibiting hESC-like morphologies were identified and
manually picked for expansion and characterization. Two
iPSC lines, AD-iPS5 and AD-iPS26B, were successfully
established from this reprogramming experiment and
characterized with respect to pluripotency-associated
properties. Both lines exhibited hESC-like morphologies
(Figure 1), telomerase activity (Additional file 2), alka-
line phosphatase (AP) activity (Additional file 3a), ex-
pression of pluripotency-associated markers NANOG,
SSEA4, TRA-1-60, and TRA-1-81 (Figure 2), expression
of pluripotency-associated genes such as NANOG,
POU5F1, SOX2, LIN28, TDGF1, DPPA4, FGF4, GDF3,
LEFTY1, LEFTY2 (Additional file 4) and the genetic fin-
gerprinting pattern of the parental NFH-46 fibroblasts
(Additional file 3b).Figure 1 Generation of human iPSCs from skin fibroblasts of a sporad
passage 4 (p4) before viral transduction. (b): Changes in morphology of NF
NFH-46 on day 24 after infection shown in circle with arrow. (d): Typical im
of AD-iPS colonies (AD-iPS-5, passage 4; AD-iPS-26B, passage 3) of one repr
passage 3(p3). (h): AD-iPSC structure in high magnification. Scale bar, 100 μFinally, the transcriptomes of the AD-iPSC lines are
similar to hESCs (H1 and H9) and to iPS lines previ-
ously generated from control NFH-2 fibroblasts [28]
(Additional file 5).
The ability to differentiate into almost all tissue types
as a hallmark of human pluripotent stem cells was analyzed
employing embryoid bodies (EBs) based differentiation in-
vitro and teratoma formation in-vivo. The AD-iPSC lines
were able to differentiate in-vitro into all three embryonic
germ layers, as detected by the expression of marker pro-
teins specific for ectoderm (b-TUBULIN III and NESTIN),
for mesoderm (Smooth Muscle Actin (SMA) and T/
Brachyury), and endoderm (Alpha feto protein (AFP)
and SOX17) (Additional file 6).
Finally, both AD-iPSC lines successfully generated
teratomas (Additional file 7). For AD-iPS5, the presence
of known endoderm-associated structures appeared un-
clear. However, this must not necessarily imply an im-
pairment of this line towards endoderm differentiation
in-vivo, since the teratoma assay itself is not standard-
ized [29]. Moreover, in the in-vitro differentiated cells
from AD-iPS5, SOX17 and AFP, both protein markers
representative of endoderm, could be detected. Thus, we
consider AD-iPS5 to be pluripotent.
Chromosomal analysis of AD-iPS5 revealed the loss of
a gonosome, probably the X chromosome, because dur-
ing mitosis they revealed a normal female karyotype.
This is in agreement with our previous study showingic Alzheimer patient. (a): Morphology of fibroblasts NFH-46 in
H-46 seven days after infection with retroviruses. (c): Changes of
age of non-embryonic stem cell like colony. (e, f): Typical morphology
ogramming experiment. (g): Typical morphology of AD-iPS colony in
m.
Figure 2 AD-iPSCs express key pluripotency-associated proteins. Two AD-iPSC lines were successfully generated with one reprogramming
experiment: AD-iPS5 (a) and AD-iPS26B (b). Both lines exhibited hESC-like morphologies, were positive for pluripotency-associated marker
proteins, such as TRA-1-81, TRA-1-60, SSEA4, and NANOG, and were negative for the differentiation-specific marker SSEA1. Scale bar, 100 μm.
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likely to contain chromosomal aberrations [28]. In nine
mitoses, a very small supernumerary marker chromosome
(sSMC) was found besides the monosomy X (Additional
file 8). It is unlikely that the presence of a small supernu-
maray maker chromosome has an effect on AD-iPS5 as
sSMCs are a common phenomenon in human. Thekaryotypes of the second iPSC line AD-iPS26B and the
parental cells NFH-46 were normal (Additional file 8).
Generation of neuronal cells from AD-iPSCs
(AD-iPS neurons)
We derived neuronal cells from AD-iPSCs in one ex-
periment to address the potential of these to reflect
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sporadic AD patients. As a control, neuronal cells were
derived from the female hESC line H9 in one differen-
tiation experiment. The neuronal cells were generated
following a recently published protocol, which requires
the exposure to TGF-β receptor (SB431542) and
MEK1/2 (PD0325901) inhibitors [30]. AD-iPSC lines
(AD-iPS5 and AD-iPS26B) and H9 were successfully
differentiated into neuronal cells. The efficiency of dif-
ferentiation varied, as AD-iPS5 showed more pro-
nounced neuronal differentiation than AD-iPS26B. All
induced neuronal cells were positive for neuronal cell
markers PAX6, NESTIN, and b-TUBULIN III as shown
in Figure 3. Most of the neuronal marker genes in the
heatmap shown in Figure 4a are expressed in a similar
manner in AD-iPSC neurons and H9 neurons, hence
confirming a neuronal differentiation of comparable
quality across all used pluripotent cell lines.Figure 3 Neuronal differentiation of AD-iPSCs. Induction of neuronal ce
factor (TGF)-β receptor and MEK1/2 for 4 weeks. Neuronal cells derived from
the expression of neuronal markers, including PAX6, NESTIN and -β-TUBULI
(c): H9. The neuronal differentiation was carried out once per AD-iPS cell linExpression of neuronal marker genes in AD-iPS neurons
and H9 neurons
The heatmap in Figure 4a shows the expression pattern
of pre-synaptic and post-synaptic genes as well as
markers of distinct subtypes of neural progenitors and
mature neuronal cell types in AD-iPS neurons and H9
neurons of one differentiation experiment conducted.
Neuronal markers FABP7, HES5, SOX2, PROM1 and
ASCL1 are expressed in AD-iPS5 and AD-iPS26B neu-
rons, however, FABP7 was not detected in H9 neurons.
GALC, a marker of oligodendrocyte progenitor cells is
expressed in all samples but lower in AD-iPS26B and
H9 neurons. MAP2, a marker of neuronal dendrites is
expressed in AD-iPS5 neurons but not in neuronal cells
of AD-iPS26B and H9. Moreover, markers of retinal gan-
glion cells (POU4F2), dopaminergic neurons (TH) and
glutamatergic neurons (SLC17A6) are expressed in AD-
iPS5 neurons (Figure 4a). In addition, neural genes suchlls by simultaneous treatment with inhibitors of transforming growth
AD-iPSCs (a): AD-iPS5 neurons and (b): AD-iPS26B neurons showed
N III in a similar fashion as neuronal cells derived from the hESC line
e or H9 cell line. Scale bar, 100 μm.
Figure 4 Expression of neuronal marker genes and genes associated with Alzheimer-related brain regions in AD-iPS neurons.
(a) Cluster analysis of neuronal marker genes in AD-iPS neurons and H9 neurons based on Euclidean distance of microarray-based gene expression
values. (b) A number of genes of the heatmap data in (a) were confirmed by real- time PCR analysis. Bars indicate the RNA level normalized to
β-ACTIN first and compared to gene expression of adult brain tissue (non-diseased, male, 21 years; Amsbio). The samples of AD-iPS neurons and
H9 neurons consisted of cRNA generated from RNA isolated from a single well of a single neuronal differentiation respectively. In addition, to our
data we analyzed AD brain RNA (male, 87 years, diagnosed AD; Amsbio). (c) Brain regions associated with genes from the AD KEGG pathway
(but neither in Huntington disease nor in Parkinson disease) down-regulated in AD-iPS5 compared to H9 neurons. (d) Brain regions associated with
genes from the AD KEGG pathway (but neither in Huntington nor in Parkinson disease) down-regulated in AD-iPS26B compared to H9 neurons.
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Figure 5 Treatment of AD neuronal cells with the γ-secretase-
inhibitor compound E (CE). Western blot analysis was used to
monitor the expression of phosphorylated tau (p-tau), non-
phosphorylated tau, GSK3α/β and phosphorylated GSK3β in AD-iPS5
neurons (INC5) and AD-iPS26B neurons (INC26B). The samples were
derived from one well of a single neuronal differentiation. The parental
fibroblast cells (NFH-46) were included as control in addition to the
positive control (PC) for p-tau represented by lysate from neuroblastoma.
β-ACTIN and GAPDH and coomassie blue staining were used to confirm
similar protein loading across samples.
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(GABA-ergic genes) on the one hand and specific AD-
related neuronal genes such as CALBINDIN1 and 2 (also
known as calretinin) as well as SST (somatostatin or
SRIF) on the other were analyzed. SRIF-positive inter-
neurons are inhibitory neurons which express GAD1
and/or GAD2 as well as CALB2 [31] and are the most
affected subtypes of neurons in AD [32]. To confirm the
array-derived heatmap data we analyzed relative gene
expression by real-time PCR (Figure 4b) using the sam-
ples of the same neuronal differentiation experiment
which were hybridized for transcriptome analysis. By
matching the gene expression to adult brain RNA, again
the H9-derived neuronal cells did not express subtype-
specific neuronal genes. The astrocyte-specific gene
GFAP was barely detected in all neural cells compared
to the mRNA level of the adult and AD brain (Figure 4b).
The neuronal cells from AD-iPS5 and AD-iPS26B were
positive for SYNAPSIN I, vGLUT2 (SLC17A6) and GAD2
and have the same transcript level as the AD brain for
CALB2 and GAD1 (Figure 4b).
Proof-of-principle drug discovery using sporadic AD-iPSC
derived neuronal cells
In addition to gene expression based analysis of
Alzheimer-related genes we evaluated the possible med-
ical relevance of our neuronal cell model in terms of
drug discovery and selection of an appropriate therapy
for sporadic AD. For this purpose, we subjected the in-
duced neuronal cells to treatment with the γ-secretase-
inhibitor Compound E (CE). The experiment was carried
out once. Two distinct concentrations were employed:
low 10 nM and high 100 nM. After one week of treat-
ment, cells were lysed directly and the protein expres-
sion levels of p-tau, tau, p-GSK3B and GSK3B were
investigated isolating samples from one well of one in-
hibitor treatment experiment conducted. Neuronal cells
derived from both AD-iPSC lines (AD-iPS5 and AD-
iPS26B) exhibited the expression of tau and p-tau, which
were undetectable in the parental fibroblasts (NFH-46)
(Figure 5). The results were confirmed using two anti-
bodies, one recognizing only p-tau and the other binding
to both the phosphorylated and non-phosphorylated
forms of tau (Figure 5). Drug treatment did not result in
any reduction of p-tau in AD-iPS5 derived neuronal
cells. On the other hand, we observed a significant re-
duction of p-tau and tau expression in neuronal cells dif-
ferentiated from AD-iPS26B compared to untreated cells
following high doses of CE (Figure 5). The expression of
both p-GSK3B and GSK3B was significantly higher in
neuronal cells compared to parental fibroblasts NFH-46
(Figure 5). However, no evident change in their expres-
sion could be identified following CE treatment. Neur-
onal cells were identified based on the expression ofNESTIN and b-TUBULIN III, however, expression was
also detected in their parental fibroblast cells, thus con-
firming previous observations in fibroblasts [33].
Differential gene expression associated with
Alzheimer-related pathways and biological processes in
AD-iPSC neurons compared to H9 neurons
Using microarray based gene expression analysis we
looked at the changes in the biological processes within
the AD-iPS neuronal cells compared to H9 neurons as
control. The hybridized samples were isolated from one
neuronal differentiation experiment. Processes related to
WNT signaling pathway and the alanine, aspartate and
glutamate metabolism, in the case of AD-iPS5 neurons
as well as the lysosome pathway and glutathion metabol-
ism in the case of AD-iPS26B appeared to be up-
regulated compared to H9 neurons. Pathways related to
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ease and the proteasome were down-regulated in both
AD-iPS neurons compared to H9 neurons (Additional
files 9 and 10). AD-iPS5 and AD-iPS26B neurons showed
up-regulated gene expression for biological processes such
as neuronal fate commitment, neuron maturation, re-
sponse to oxygen radical and/or response to reactive oxy-
gen species (Additional file 9). In contrast to that, the
UPS, apoptosis, and oxidative phosphorylation emerged as
down-regulated biological processes (Additional file 10).
Overall, these data suggest that AD neuronal cells exhibit
alterations in key signaling pathways related to cell death,
anabolism and catabolism in comparison to the healthy
control.
AD-iPSC neurons show a distinct gene expression pattern
of Alzheimer-associated genes of genome wide association
studies compared to H9 neurons
To further analyze the reflection of Alzheimer-specific
gene expression patterns in our iPSC-based model sys-
tem we performed data mining to extract disease rele-
vant gene expression using an Alzheimer gene list
recently published by the European Alzheimer’s Disease
Initiative (EADI) [34]. The cluster analysis in Figure 6
showed that AD-iPS5 neurons and AD-iPS26 neurons
were more similar to each other than to H9 neurons. Ba-
sically there are six gene clusters: (i) a cluster of genes
expressed in all experiments such as APOE and APP, (ii)
a cluster of genes expressed in no experiment such as
CASS4 and CR1, (iii) a cluster of genes expressed in both
AD-iPSC neuron experiments but not in the H9 neuron
experiment such as PTK2B and PICALM, (iv) a single-
ton cluster of HLA-DRB5 not expressed in both AD-iPS
neuron experiments but expressed in the H9 neurons,
(v) a singleton cluster of MEF2C not expressed in AD-
iPS26B experiments but expressed in AD-iPS5 and the
H9 neurons and (vi) a cluster of genes expressed in AD-
iPS26B neurons but not in AD-iPS5 and H9 neurons
containing genes such as SLC24A4 and ABCA7.
AD-iPSC neurons show down-regulation of genes
involved in Alzheimer’s, Huntington’s and Parkinson’s
disease compared to H9 neurons
Analysis of differences in the iPS-derived neurons
when compared to the annotations Alzheimer’s disease,
Parkinson’s disease and Huntington’s disease revealed that
most genes down-regulated in AD-iPS5 vs. H9 neurons
(Figure 7) and AD-iPS26B vs. H9 neurons (Figure 8) were
common to all three neural disorders. Exclusively associ-
ated with Alzheimer’s disease were 16 genes in AD-iPS5
vs. H9 neurons and 10 genes in in AD-iPS26B vs. H9 neu-
rons. These genes were APP, APOE, PSENEN, CDK5,
HSD17B10, TNFRSF1A, PPP3CB, PPP3CC, CHP, GAPDH,
CAPN2, CAPN1, ATP2A2, GSK3B, CALM3 and CALM2in the experiment AD-iPS5 vs. H9 neurons and APP,
CDK5, HSD17B10, CHP, GAPDH, NAE1, ATP2A2,
GSK3B, CALM3 and CALM2 in the experiment AD-
iPS26B vs. H9 neurons.
Brain allocation of Alzheimer-specific genes down-regulated
in AD-iPSC neurons compared to H9 neurons
The expression in different brain regions of the Alzheimer-
exclusive genes that were found to be down-regulated in
AD-iPSC neurons of one differentiation experiment were
investigated using the GNF/Atlas organism part. The ex-
pression of the largest set of genes was allocated to pons
with 12% in the case of AD-iPS5 neurons for the genes
APOE, APP, ATP2A2, CALM2, CALM3, CAPN2, CDK5,
GAPDH, GSK3B and PPP3CB (Figure 4c) and 13% in AD-
iPS26B neurons for the genes APP, ATP2A2, CALM2,
CALM3, CDK5, GAPDH and GSK3B (Figure 4d). This
was followed by globus pallidus with 9% in AD-iPS5
neurons for the genes APP, ATP2A2, CALM2, CALM3,
CDK5, GAPDH and PPP3CB and 9% in AD-iPS26B neu-
rons for the genes APP, ATP2A2, CALM2, CALM3,
CDK5 and GAPDH. The percentages for medulla oblon-
gata, prefrontal cortex and amygdala were found to be
5–8% (Figure 4c and d).
An Alzheimer-relevant functional protein association
network can be built using an Alzheimer-specific gene
set down-regulated in AD-iPSC neurons compared to H9
neurons
To further specify the reflected Alzheimer-related pheno-
type in our iPSC-based neuronal disease model we con-
structed protein association networks by means of the
gene expression data generated from one differentiation
experiment. Therefore, protein-interaction networks were
generated using genes annotated with AD pathway that
are down-regulated in AD-iPS5 neurons vs. H9 neurons,
in AD-iPS26B neurons vs. H9 neurons as well as the over-
lap of both datasets. We successfully modeled the associ-
ation of Alzheimer-related proteins within our cellular
system in both AD-iPS neuronal differentiation experi-
ments through the subsequent comparison to non-AD
embryonic stem cell line H9 neuronal cells and further
network construction by applying STRINGv9. The gener-
ated networks in Figures 9, 10 and 11 depict associations
between proteins in a color code. The color of the line be-
tween proteins represents the following evidence categor-
ies: neighborhood in the genome (dark green line), gene
fusion (red line), co-occurrence across genomes (dark blue
line), co-expression (black line), experimental/biochemical
data (purple line), association in curated databases (light blue
line) and co-mentioning in PubMed abstracts/textmining
evidence (light green line).
The protein association networks built from genes
down-regulated in AD-iPS5 vs. H9 neurons in Figure 9
Figure 6 Expression of Alzheimer risk genes in AD-iPSC derived
neurons. Cluster analysis of Alzheimer risk genes in experiments
AD-iPS5 neurons, iPS26B neurons and H9 neurons of one neuronal
differentiation experiment each. Up and down-regulated transcripts
are depicted in red and green, respectively. RNA from AD-iPS5
neurons, AD-iPS26B neurons and H9 neurons was hybridized onto
an Illumina human-8 BeadChip version 3. Alzheimer-associated
genes known from genome wide association studies were filtered
from the microarray experiments of AD-iPS5 neurons, AD-iPS26B
neurons and H9 neurons. Illumina detection p-values were mapped
to a binary scale (0 = not expressed if p-value > 0.05, 1 = expressed if
p-value < = 0.05). These values were clustered via the R heatmap2
function using Euclidean distance as distance measure.
Figure 7 Gene expression associated with Alzheimer, Parkinson
and Huntington disease in AD-iPS5 neurons. Venn diagram of
down-regulated genes in the comparison AD-iPS5 vs. H9 neurons in
KEGG pathways Alzheimer disease (AD), Parkinson disease (PD) and
Huntington disease (HD). RNA from AD-iPS5 neurons and H9
neurons of one neuronal differentiation experiment was hybridized
onto an Illumina human-8 BeadChip version 3. Functional annotation
of significantly down-regulated genes from the experiments AD-iPS5
neurons vs. H9 neurons was performed with the DAVID Bioinformatics
Resources 6.7. ips5 vs. H9: numbers of significant genes from KEGG
pathways for ALzheimer, Parkinsons and Huntington.
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AD-iPS26B vs. H9 neurons network in Figure 10. These
proteins are NDUFB10, NDUFA9, NDUFB8, NDUFB9,
ATP5G1, CAPN2, UQCRQ, NDUFA1, CAPN1, NDUFS7,
SDHB, TNFRSF1A, CASP3, APOE, SDHD, PPP3CB,
PPP3CC and PSENEN (Figure 9). However, the two pro-
teins NDUFA6 and NAE1 are only part of a network built
from the AD-iPS26B vs. H9 neurons dataset (Figure 10).
Interestingly, both interaction networks contain APP and
GSK3Β as well as CDK5 and HSD17B10. In the AD-iPS5
vs. H9 neurons and not in the AD-iPS26B vs. H9 neurons
network APP is depicted to be associated with CASP3 and
APOE by experimental evidence and textmining evidence
Figure 8 Gene expression associated with Alzheimer, Parkinson
and Huntington disease in AD-iPS26B neurons. Venn diagram of
down-regulated genes in the comparison AD-iPS26B vs. H9 neurons
in KEGG pathways Alzheimer disease (AD), Parkinson disease (PD)
and Huntington disease (HD). RNA from AD-iPS26B neurons and H9
neurons was hybridized onto an Illumina human-8 BeadChip version
3. Functional annotation of significantly down-regulated genes from
the experiments AD-iPS26B neurons vs. H9 neurons was performed
with the DAVID Bioinformatics Resources 6.7. ips26 vs. H9: numbers
of significant genes from KEGG pathways for ALzheimer, Parkinsons
and Huntington.
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dence (Figure 9). In addition, only the AD-iPS26B vs. H9
neurons network depicts the association of APP and
NAE1 through co-expression, database, experimental and
textmining evidence (Figure 10). Furthermore, only in the
AD-iPS5 vs. H9 neurons and not in the AD-iPS26B vs. H9
neurons network functional associations between CASP3
and CDK5, CAPN2, TNFRSF1A, CALM3, APOE and
COX4I1 that are proven by textmining evidence could be
found. TNFRSF1A which is only a part of the network in
Figure 9 is associated with CDK5, CALM3 by textmining
evidence and with CASP3 with additional database evi-
dence. Exclusively in this protein association network
APOE, which plays a major role in Alzheimer pathogen-
esis, is associated with CASP3, CALM3, CALM2 and
GAPDH by textmining evidence whereas CAPN2 is asso-
ciated with CASP3, CALM2 and CALM3 by textminig
evidence. Surprisingly, no associations could be found for
CAPN1 in this network. Additional proteins only part of
the AD-iPS5 vs. H9 neurons network are PPP3CC and
PPP3CB both of which are associated with each other by
co-occurrence, database, experimental and textmining evi-
dence. They are associated with CALM2 and CALM3
with experimental and textmining evidence. PSENEN, a
subunit of the γ-secretase complex, occurs only in this
protein association network and is associated withUQCRH via textmining and co-expression evidence.
Additional proteins exclusively part of the AD-iPS5 vs.
H9 neurons network are NDUFS7, NDUFA9, NDUFB8,
NDUFB10, NDUFA1, NDUFB9, UQCRQ, ATP5G1,
SDHB and SDHD. These are part of a complex protein
association network-cluster mainly consisting of pro-
teins involved in oxidative phosphorylation (Figure 9).
Interestingly, NDUFA6 is only part of the protein asso-
ciation network based on the genes in the AD-iPS26B
vs. H9 neurons dataset (Figure 10).
The network built from the genes overlapping between
the AD-iPS5 vs. H9 neurons and AD-iPS26B vs. H9 neu-
rons datasets in Figure 11, shows associations with experi-
mental and textmining evidence of APP with HSD17B10,
GAPDH, CDK5, GSK3B and SNCA. In addition, database
evidence to prove the association of APP, SNCA and
GAPDH could be found. Associations with textmining
evidence between CDK5 with CALM2 and CALM3 as
well as between GAPDH and ATP2A, CALM2, CALM3,
SDHA, ATP5B and ATP5J could be found by our method.
Furthermore, the interaction of GAPDH with ATP5B and
ATP5J is associated with co-expression evidence in this
network. GAPDH is associated with CHP via experimental
evidence. Additional Alzheimer-related genes are intercon-
nected to a complex protein association network clus-
ter similar to Figures 9 and 10. consisting of proteins
like NDUFB3, ATP5E, NDUFB5, UQCRC, NDUFB6,
NDUFB7, ATP5B, NDUFAB1, NDUFB2 that are mainly
involved in oxidative phosphorylation or in the electron
transport chain in mitochondria. In our Alzheimer-related
protein association network in Figure 11 we found experi-
mental evidence association between SNCA and NDUFB6
as well as the co-expression evidence interactions of
HSD17B10 with NDUFV2, NDUFB7, UQCRH and
ATP5J. These associations connect Alzheimer-specific
APP, GSK3B, CDK5, CALM2, CALM3 and ATP2A2
with proteins involved in Alzheimer related failure of
the function of mitochondrial processes of the respira-
tory chain of the protein association cluster. A further
association to proteins involved in oxidative phorphor-
ylation are the interactions of GAPDH with ATP5J,
ATP5B and SDHA (Figure 11).
A subset of UPS-related genes is down-regulated in
AD-iPSC neurons compared to H9 neurons
The cluster analysis of UPS-associated genes assembled
both AD-iPS neurons datasets into a cluster separated
from the H9 neurons. Genes were divided into three clus-
ters (i) 36 genes which have lower gene expression values
in both AD-iPS neuron compared to H9 neurons, among
them PSMC1, PSMA5, NEDD8. (ii) 2 genes characterized
by higher expression in both AD-iPS neuron compared to
H9 neurons: PSMD5, PSMB9. (iii) 25 genes the expression
of which varies between the three samples. The last cluster
Figure 9 Alzheimer-related protein association network in AD-iPS5 neurons. Protein association network retrieved from STRING v9 using
genes from the Alzheimer disease pathway down-regulated in the AD-iPS5 neurons vs. H9 neurons comparison of one neuronal differentiation
each. The network circles represent proteins. The lines between the circles show the functional association. Co-expression evidence: black,
database evidence: light blue, textmining evidence: yellow, experimental evidence: purple, co-occurrence evidence: blue, neighborhood evidence:
green, fusion evidence: red.
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in H9 neurons and AD-iPS5 neurons but not in AD-
iPS26B neurons - PSME2, PSMD8, (ii) 9 genes with high
expression values in H9 neurons and AD-iPS26B neurons
but not in AD-iPS5 neurons - PSMD14, PSMD4, (iii) 5
genes with a low gene expression values in H9 neurons
and AD-iPS26B neurons and a high gene expression in
AD-iPS-5 neurons - PSMD4, SUGT1, (iv) 6 genes with
low gene expression values in H9 neurons and AD-iPS5
neurons and a high gene expression values in AD-26B
neurons - PSME1, PSMB10 (Figure 12).
Discussion
Little is known about the clinical onset and course of
sporadic AD due to the limited insight and access to
brain-derived neuronal cells from patients afflicted with
neurodegenerative diseases. Therefore, it is essential that
we develop new in-vitro-based experimental models that
may reflect affected nerves in the brain. Thus, an earlydiagnosis could help in this regard to treat the affected
individuals effectively and to test preventive approaches
of sporadic Alzheimer’s disease treatment. In recent
time, several research groups independently and success-
fully differentiated somatic cells of AD patients directly
or by iPSC-based approaches into neuronal cells, and ex-
amined them with respect to the molecular basis of dis-
ease development [22-26].
The results of these studies lead to valuable insights
regarding understanding of AD molecular disease, given
that these innovative and predictive patient cell models
displayed the AD phenotype [22]. In our current study,
we confirmed that dermal fibroblasts derived from spor-
adic AD patients could be induced to a pluripotent state
(iPSCs) and further differentiated into neuronal cells in
one reprogramming and one neuronal differentiation ex-
periment per derived AD-iPSC clone. The transcrip-
tomes of the derived neuronal cells were characterized
by the expression of neuronal markers such as GALC,
Figure 10 Alzheimer-related protein association network in AD-iPS26B neurons. Protein association network retrieved from STRING v9
using genes from the Alzheimer disease pathway down-regulated in the AD-iPS26B neurons vs. H9 neurons comparison of one neuronal differentiation
each. The network circles represent proteins. The lines between the circles show the functional association. Co-expression evidence: black, database
evidence: light blue, textmining evidence: yellow, experimental evidence: purple, co-occurrence evidence: blue, neighborhood evidence: green, fusion
evidence: red.
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gene expression patterns when compared to control
neuronal cells. We successfully generated an Alzhei-
mer’s disease-related protein association network using
detected AD-related alterations of the transcriptome.
As a control we used neuronal cells generated from the
female embryonic stem cell line H9 in our study. Thisis a very clean background, it might be argued that
some of the disease associated effects we see in our
model come from differences between embryonic stem
cells and iPS cells in general or are related to the ad-
vanced age of the AD patient (82-years-old) whose
cells were used in this study. An effect of the age-
related high mutation load in the parental fibroblast
Figure 11 Overlapping Alzheimer-related protein association network of AD-iPS5 neurons and of AD-iPS26B neurons. Protein association
network of genes down-regulated in both AD-iPS5 neurons vs. H9 neurons and in AD-iPS26B neurons vs. H9 neurons comparisons of
one neuronal differentiation. Protein interaction network retrieved from STRING v9 using genes from the Alzheimer disease pathway down-regulated
in AD-iPS5 vs. H9 neurons and in AD-iPS26B vs. H9 neurons experiments. The network circles represent proteins. The lines between the circles show
the functional association. Co-expression evidence: black, database evidence: light blue, textmining evidence: yellow, experimental evidence: purple,
co-occurrence evidence: blue, neighborhood evidence: green, fusion evidence: red.
Hossini et al. BMC Genomics  (2015) 16:84 Page 13 of 22compared to H9 cannot be excluded but could be sig-
nificant since AD is an aged-related disease and as
such one would expect a higher mutation load in pa-
tients. An age-matched control iPS cell line would have
been an alternative to H9 for our study. Many iPSC-
based disease models compare the effect of mutations
in a disease associated gene within the same genetic
background. The parental fibroblasts used for AD-
iPSC generation in this study did not carry any muta-
tions in Alzheimer-related genes which excluded thepossibility to use the same genetic background in our
case. Based on the fact that FABP7 a gene involved in
neuronal development [35] is not expressed in H9 neu-
rons, one could argue that the mixture of neuronal
subtypes found in the neuronal differentiation of H9 is
distinct from the neuronal differentiations of AD
iPSCs. Despite possible differences in neuronal differ-
entiation efficiencies or mixture of neuronal subtypes
we see altered expression of AD-related genes in two
neuronal differentiations of AD patient fibroblast derived
Figure 12 UPS-associated gene expression in AD-iPSC neurons.
Cluster analysis based on Pearson correlation of UPS-related genes in
AD-iPS neurons and H9 neurons. Up and down-regulated transcripts
are depicted in red and green, respectively. RNA from AD-iPS5 neurons,
AD-iPS26B neurons and H9 neurons of one well of one neuronal
differentiation each was hybridized onto an Illumina human-8 BeadChip
version 3. Known proteasome-related genes were selected from the
microarray experiments of AD-iPS5 neurons, AD-iPS26B neurons and
H9 neurons. Their Illumina average signal intensities were transformed
to a logarithmic scale (log2) and clustered with the R heatmap2 function
using Pearson correlation as similarity measure.
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H9 used as a control.
At the protein level, the neuronal cells which we de-
rived from sporadic AD-iPSCs in a single neuronal dif-
ferentiation experiment expressed p-tau and GSK3B,
both valid as neuropathological proteins. Analysis of the
brain of sporadic AD patients often shows intracellular
accumulation of hyperphosphorylated tau proteins, an
early event preceding the appearance of NFT in AD [6].
Physiological, GSK3β is a multifunctional protein kinase
that phosphorylates a variety of substrates including the
tau protein, which is associated with neuronal-specific
microtubules. Surprisingly, in our cell model we ob-
served the up-regulation of both isoforms of the GSK3α
and GSK3β protein as well as clear formation of abnor-
mal p-tau (Thr 231) in AD-iPSC derived neuronal cells
in comparison to their parental fibroblast cells, which
expressed minute levels of GSKαβ and no tau.
In a recently published study on neuronal cells derived
from AD-iPSC of familial AD, abnormal p-tau expres-
sion was not detected by western blotting, probably due
to the short time scale in culture [25]. Nevertheless, an-
other study could show increased p-tau in both familial
and one sporadic AD sample, however measured by the
MSD phospho tau kit [22]. In the same study high
amounts of GSK3β were measured in induced neuronal
cells from an AD donor, this is in accordance with the
observation in our AD-iPSC derived neuronal cells.
Global gene expression analysis revealed up-regulation
of AD-related pathways in AD-iPS neurons of one neur-
onal differentiation experiment for each AD-iPS cell line
such as WNT, the lysosome signalling pathway and glu-
tathion metabolism all of which have been shown to be
altered in Alzheimer’s disease [36-38]. Interestingly, we
detected altered expression of genes that are involved in
the alanine, aspartate and glutamate metabolism. A very
recent work showed through meta-analysis of genome-
wide association studies involving 2540 Alzheimer cases
that changes in glutamate metabolism are overrepre-
sented in data from patients with AD [39].
In addition, biological processes involving response to
oxygen radical and response to oxidative stress were
up-regulated in our sporadic AD model. Indeed these
processes are known to be up-regulated in Alzheimer’s
disease [40]. Moreover, biological processes such as
neurogenesis appeared to be up-regulated, underlining
successful neuronal differentiation. The mixture of neur-
onal subtypes generated by our neuronal differentiation
experiments might vary as we did not carry out subtype
specific differentiations.
A cluster analysis of the expression of AD-associated
genes recently published confirmed differential expres-
sion in the generated AD-iPS neurons compared to H9
neurons [34].
Hossini et al. BMC Genomics  (2015) 16:84 Page 15 of 22Even though 19 of 26 genes of the cluster analysis of
Alzheimer-related genes seemed to be expressed in a
similar manner in H9 neurons compared to AD-iPS
neurons, the transcriptomes of AD-iPS neurons were
more similar to each other than to H9 neurons despite a
possible variation of neuronal subtype mixtures in the
conducted neuronal differentiation experiments. Differ-
ential behavior between both AD-iPS neurons experi-
ments and the H9 neurons experiment points to genes
whose up-regulation (PTK2B, PICALM, IL8) or down-
regulation (HLA-DRB5) may play a major role in devel-
opment of the disease in this patient.
While PTK2B, IL8 and HLA-DRB5 are clearly involved
in Alzheimer pathology [34,41,42], there are controver-
sial studies about the involvement of PICALM in Alzhei-
mers disease [43,44].
The genes EXOC3L2, CLU, CR1 and TNK1 although
associated with AD were not found to be expressed in
AD-iPS neurons. The gene EXOC3L2 has been associ-
ated with late onset Alzheimer disease (LOAD) in
GWAS [45]. However, it could be shown that the associ-
ation is likely to be caused by the close location to APOE
and there was found no more evidence after adjustment
for APOE [46]. Our results showing no expression for
EXOC3L2 in AD-iPS5 and AD-iPS26B neurons are in
line with that finding.
The AD-association with TNK1 which was also not
expressed significantly in our experiments is unclear as
several studies report ambiguous results [47,48].
In contrast to that, differentially expressed genes in
AD-iPS neurons revealed the down-regulation of path-
ways annotated to Alzheimer’s disease, Huntington’s disease
and Parkinson’s disease. The overlap of down-regulated
gene expression related to Alzheimer’s disease, Huntington’s
disease and Parkinson’s disease in our AD-iPS neuronal
cells in Figures 7 and 8 supports the notion of a patho-
logical mechanism common to these three neurodegener-
ative diseases [49].
Sixteen Alzheimer’s disease-specific genes could be
confirmed to be down-regulated in AD-iPS5 (Figure 7)
and 10 genes in AD-iPS26B compared to H9 neurons
(Figure 8). These genes could be allocated to brain re-
gions which are affected by Alzheimer’s disease depicted
in Figure 4b and c. In both AD-iPS neuron experiments
the largest number of Alzheimer-related genes was allo-
cated to pons. Indeed, pons has been reported to have a
smaller volume in patients with familial Alzheimer’s dis-
ease [50]. The second largest gene set was allocated to
the brain region globus pallidus for both AD-iPS neur-
onal cells, a brain region which was reported to be in-
volved in Alzheimers disease [51]. Finally, the medulla
oblongata and amygdala brain regions which show
deregulated gene expression in AD iPS neurons in our
model were reported to be affected in AD [52,53].We could successfully generate a protein association
network consisting of AD-specific genes down-regulated
in AD-iPS neurons compared to H9 neurons. The net-
works reflects the differences between the two AD-iPS
neurons as there are more Alzheimer risk genes (for ex-
ample, PSEN and APOE) present in the network built
from AD-related genes down-regulated in AD-iPS5 neu-
rons against healthy H9 neurons. Despite these differences
the construction of a STRING-based protein association
network representing the AD phenotype was possible with
our approach for both AD-iPS neuron cell populations.
APP, a protein which plays a central role in the pathology
of Alzheimer’s disease, is part of the protein association
network in both AD-iPS neuron cultures as well as in the
association network built from the overlap of both experi-
ments. Several studies report protein interaction networks
characterizing the molecular disease phenotype in post
mortem brains of sporadic AD patients or patients with
familial Alzheimer disease [54,55]. Despite the usefulness
of these networks for gaining insights into molecular
changes in the final stage of AD, no information can be
drawn about the early molecular pathology of AD with
this approach. Generating iPS from AD patients in the
early stage of the disease would allow modeling disease-
specific changes in the AD-related protein association net-
work over time, which provides valuable information of
the development of new therapy approaches at early
stages. So far, our study is the first demonstration of a pro-
tein interaction network of AD-iPS neurons derived from
skin cells from an 82-year-old sporadic AD patient. Mod-
eling sporadic AD using iPS technology as presented here
enables us to formulate hypotheses to increase our un-
derstanding of AD pathogenetic mechanisms and test
them by monitoring the effect on the protein associ-
ation network.
Next to differential gene expression of AD-specific
genes in AD-iPS derived neurons we detected the down-
reglation of genes in AD-iPS neuronal cells that play a
major role in the UPS. Our data revealed that the major-
ity of the UPS-related genes are down-regulated in AD-
iPS neurons compared to H9 neurons, suggesting that
UPS functionality is lowered in our AD-iPS neurons but
not in healthy H9 neurons. Indeed, UPS deficiency has
been associated with AD pathology [18]. These results
suggest that our Alzeimer model very likely reflects
UPS-related features of AD pathology which are most
probably present in the neuronal cells of the sporadic
AD patients.
Furthermore, the UPS-related gene expression data sug-
gests that both the constitutive and inducible proteasome
play a role in AD pathology. This is reflected in the lower
gene expression of the main constitutive subunits of the
proteasome PSMB5/6/7 in iPS-derived neuronal cells
from the AD patient compared to H9 neurons and the
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rons compared to H9 neurons. The genes PSMB8 and
PSMB10, the expression of which is higher than in H9
neurons only in the case of AD-iPS26B neurons are
probably less important in AD-related pathology driven
by the UPS as their expression showed a higher vari-
ation. Indeed, constitutive proteolytic activities have
been reported to be decreased in AD brains, meanwhile
the composition of the proteasome complex is not af-
fected [56]. Interestingly, in contrast to the constitutive
proteolytically-active subunits, the inducible ones have
been reported to be highly expressed in the hippocampus
(HC) of severe diseased AD patients (Braak stage ≥ III)
[57,58].
In addition, we found that the expression of the gene
NEDD8 is down-regulated in AD-iPS neurons compared
to the control. It is known that NEDD8 plays a role in
AD pathology. The APP binding protein-1 (APP-BP1) is
also increased in the AD-affected HC [16]. APP-BP1 as-
sociates with UBA3 resulting in an E1-like activating
enzyme for the process of NEDD8, an ubiquitin-like pro-
tein [16]. However, NEDD8 was additionally found to be
present in high amounts in neurofibrillary tangles (NFTs)
and senile plaques from a patient with AD [59,60], which
would suggest that NEDD8 is up-regulated in AD, which
we do not see in our iPS-based model. Our data suggests
that UPS dysfunction may occur early in AD pathogenesis
eventually leading to cellular protein aggregates later on.
Using our neuronal cell model, we provide a proof of
principle that neuronal cells differentiated from patient
dermal fibroblasts-derived iPS cells offer a valuable tool
for modeling early molecular pathology of AD, screening
and development of appropriate drugs for the treatment
of AD in the future. However, our results suggest that
the different iPSC clones even derived from the same in-
dividual may give rise to different responses which is
reflected in the differences between the two protein as-
sociation networks generated from the gene expression
data of the two different AD-iPS clones differentiated to
neuronal cells in one experiment each. In our study we
generated two sporadic AD-iPSC lines: one (AD-iPS26B)
exhibited complete teratoma formation and normal
karyotype whilst the other cell line (AD-iPS5) showed
karyotype abnormalities and failed to differentiate into
endoderm in-vivo. Due to the fact that the teratoma
assay is not standardized [29] the trend now is towards
a transcriptome-based classification of pluripotency
(PluriTest) rather than the traditional teratoma-based
assay [61]. Interestingly, only AD-iPS26B responded to
the γ-secretase-inhibitor CE treatment in one inhibitor
treatment experiment. This would suggest that the se-
lection of iPSC clones is critical to enable the gener-
ation of results that are clinically relevant. However,
neurons from AD-iPS5 showed a higher number ofAD-related genes that are deregulated compared to
AD-iPS26B neurons as reflected in the different pro-
tein association networks built from these two neuronal
cell differentiation experiments. Therefore, the failure to
respond to CE could be a reflection of this difference in
AD-related gene expression between the two clones. Our
findings, although based on a limited number of AD-
iPSCs, have highlighted the fact that molecular pathology
of sporadic Alzheimer can be modelled in disease-related
protein association networks by means of iPSC technology
and transcriptome analysis. Abnormalities of the karyo-
type in the parental AD-iPS cells should be avoided but as
in our case do not necessarily lead to a distortion of gene
expression-based AD protein association networks with
this approach.
Conclusion
In summary, we have generated patient-specific pluripo-
tent stem cells from skin fibroblasts of an 82-year-old
woman suffering from sporadic AD and induced these
to differentiate into neuronal cells. The patient-derived
cells recapitulated key features of the disease, including
the expression of p-tau, GSK3β, down-regulation of AD-
related genes and altered biological features caused by
differential expression of genes involved in e.g. the UPS
or response to oxidative stress.
The majority of the UPS genes are down-regulated in
AD neurons, thus supporting the idea that dysfunctions
in this system may occur early in AD pathogenesis and
then lead to cellular protein aggregates at later stages of
the disease. Additionally, a few genes were distinctly up-
regulated in neurons derived from the two AD-iPSC
lines. This may suggest that these genes are less important
for AD pathogenesis as their expression varies among dif-
ferent neuronal lines.
In essence, we have successfully generated an Alzheimer-
related protein association network using characteristic
gene expression patterns detected in AD-iPSCs compared
to a healthy control of one neuronal differentiation experi-
ment. Our results lend further support to the fact that
neuronal cells differentiated from iPSCs from sporadic
AD patients in part recapitulate the neuropathological
processes of the disease. We anticipate that iPSC-based
modeling of AD as demonstrated here can be useful for
formulating testable hypotheses that might eventually
enhance our meager knowledge of the molecular basis
of its progression and should eventually lead to the de-
velopment of new drugs to prevent or treat this disease.
Methods
Ethics statement
Full-thickness skin biopsy was resected from the forearm
of the patient undergoing surgery. The Charité University
Medicine Berlin ethics committee specifically approved
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from the guardian of the participant including written in-
formed consent.
Cell culture
Adult dermal fibroblasts from an 82-year-old woman
(NFH-46) suffering from late-stage AD under no medica-
tion and with no family history were obtained from 6 mm
full-thickness skin biopsies originating from the sun-
protected forearm inner side. The skin specimens were in-
cubated in dispase solution (2.4 U/ml) overnight at 4°C.
After separation of epidermis, primary dermal fibroblasts
were isolated from dermis by enzymatic digestion and
were expanded within 4 weeks. The dermal fibroblasts
were cultured in DMEM supplemented with 10% fetal calf
serum (FCS), nonessential amino acids, L-glutamine, peni-
cillin/streptomycin and sodium pyruvate (all from Invitro-
gen, Carlsbad, CA). The human embryonic stem cell
(hESC) lines H1 and H9 were purchased from WiCell,
Madison, WI (#WA01 and #WA09, respectively). Control
iPSCs (OiPS3 and OiPS6) have recently been generated
from the skin of an 84-year-old female (NFH-2 fibroblasts)
[62]. hESCs and iPSCs were cultured in hESCs media con-
taining KO-DMEM supplemented with 20% knockout
serum replacement, nonessential amino acids, L-glutamine,
penicillin/streptomycin, sodium pyruvate, 0.1 mM β-
mercaptoethanol (all from Invitrogen) and 8 ng/ml
basic fibroblast growth factor (bFGF) (Preprotech;
Rocky Hill, NJ). Cultures were maintained on mitomy-
cin C-inactivated mouse embryonic fibroblasts (MEFs)
and passaged manually. For experiments feeder layer-free
iPSCs and hESCs were grown on dishes coated with
Matrigel (BD; San Diego, CA) in MEF-conditioned media
(CM). All cultures were kept in a humidified atmosphere
of 5% CO2 at 37°C. Experiments were carried out with
primary fibroblasts at passages 3–6 and AD-iPS cells at
passages 8–18.
Retroviral transduction into fibroblasts and derivation of
iPSCs
NFH46-derived iPSCs (AD-iPS5 and AD-iPS26B) were
obtained using the Yamanaka retroviral cocktail [27] in
one reprogramming experiment. Briefly, pMX vector-
based OCT4, KLF4, SOX2 and c-MYC retroviruses were
generated using 293 T cells, according to the conventional
CaCl2 transfection protocol. 200,000 fibroblasts were used
as input for reprogramming experiments and seeded into
six wells of a six well plate. Four weeks after transduction,
hESC-like colonies were manually picked and expanded
for characterization as previously described [27,28].
DNA fingerprinting analysis
In order to confirm somatic origin and to exclude cross
reaction with hESCs, DNA fingerprinting analysis wasperformed as previously described [28]. 100 ng of gen-
omic DNA isolated from one well per AD-iPS cell line
were used for PCR amplification, following this program:
94°C for 1 min, 55°C for 1 min, 72°C for 1 min, for 40 cy-
cles, using Dyad thermal cycler (BioRad, Hercules, CA).
PCR products were resolved in 2.8% agarose gels to
examine the differential amplicon mobility for each pri-
mer set: D7S796, repeat (GATA)n, average heterozygos-
ity = 0.95. The primer sequences are listed in Additional
file 11.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction based
gene expression analysis of pluripotency-associated and
neural genes was carried out using the ABI PRISM SDS
2.1 software (Applied Biosystems, Foster City, CA) and
Microsoft Excel [63]. The primer sequences are listed in
Additional file 11. The data are presented as relative
gene expression based on the ΔΔCt calculation over
NFH-46 (Additional file 4) or adult brain tissue (Figure 4)
with respect to standard error of mean (SEM). The real
time PCR analysis was performed using triplicates for
each repetition (n = 3). Real time PCR to confirm pluri-
potency gene expression was performed on 3 independ-
ent wells of AD-iPS5 and AD-iPS26B respectively. Each
iPS line was split from one well into the three wells, and
expanded, prior to RNA isolation. The RNA samples
were not pooled. The real time PCR confirming the ex-
pression of neuronal markers was performed using
cRNA derived from RNA of one neuronal differentiation
of a single well of AD-iPS 5, AD-iPS 26B and H9
respectively.
Confirmation of functional pluripotency in-vitro
For in-vitro differentiation, embryoid bodies (EBs) were
generated from AD-iPSCs in one differentiation experi-
ment each by cell harvesting and seeding onto low-
attachment dishes in DMEM supplemented with 10%
FCS, nonessential amino acids, L-glutamine, penicillin/
streptomycin and sodium pyruvate (all from Invitrogen)
without bFGF supplementation. One week later, EBs
were plated onto gelatin-coated tissue culture dishes,
grown for additional ten days, and analyzed by
immunofluorescence-based detection of the expression
of germ layer-specific proteins.
Confirmation of functional pluripotency in vivo
In-vivo teratoma assays were performed by EPO-Berlin
GmbH, Berlin-Buch, Germany. AD-iPSCs were collected
by trypsinization, washed and injected s.c. into NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ mice, commonly known as
NOD scid gamma (NSG). Histological analysis was per-
formed at the Institute for Animal Pathology, Berlin,
Germany.
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Pluripotent stem cells (iPSCs and hESCs) were mechanic-
ally dissociated and grown in MEF-conditioned medium
(CM) on matrigel-coated dishes for 72 h. Induction of
neuronal cells was performed by adding 10 μM SB431542
(SB, TGFβ receptor inhibitor) and 1 μM PD0325901 (PD,
MEK1/2 inhibitor) (both from Sigma-Aldrich, Deisenho-
fen, Germany) in the absence of bFGF [30]. The cells were
grown for additional four weeks under daily medium
change. The obtained neuronal cells were fixed for im-
munostaining or used for drug treatment. The neuronal
differentiation and subsequent inhibitor treatment were
carried out once per AD-iPS cell line and for the control
H9.
Alkaline phosphatase analysis and immunofluorescence
staining
Alkaline phosphatase (AP) activity was visualized by the
commercial AP staining kit (Millipore #SCR004; Schwalbach,
Germany) according to the manufacturer’s instructions. In
order to characterize pluripotency of all AD-iPSC col-
onies, the cells were fixed in phosphate-buffered saline
(PBS) containing 4% paraformaldehyde (Science; Munich,
Germany) for 20 min at room temperature, subsequently
washed twice with PBS without Ca2+ and Mg2+, blocked
with 10% FCS serum (Vector; Loerrach, Germany) and
0.1% Triton X-100 (Sigma-Aldrich, Germany) in PBS and
proceeded to immunocytochemistry with primary anti-
bodies against OCT4, SOX-2, KLF-4, SSEA1, SSEA4, TRA-
1-60 and TRA-1-81 from the hESC characterization kit
(all 1:100, Millipore #SCR004), NANOG (1:100, Abcam
#ab62734, Cambridge, UK), Smooth-Muscle-Actin (SMA)
(1:100, Dako #M0851, Hamburg, Germany), Alpha-
Fetoprotein (AFP) (1:100, Sigma-Aldrich #WH0000174M1),
SOX17 (1:50, R&D #AF1924, Minneapolis, MN), PAX6
(1:300, Covance #PRB-278P, Münster, Germany), Nestin
(1:200, Chemicon #MAB5326, Nürnberg, Germany), b-
Tubulin III (1:1000, Sigma-Aldrich #T8660), Brachyury
(T) (1:50, R&D #AF2085). Alexa-488-conjugated second-
ary antibodies were used (1:300, Invitrogen #A11001).
Nuclei were counter-stained with DAPI (200 ng/ml,
Invitrogen #H357) and visualized using the confocal
microscope LSM510 (Carl Zeiss, Jena, Germany).
Western blot
Human AD-iPSCs and their corresponding fibroblast
cells were detached from cell culture dishes by incuba-
tion with AccutaseTM (Millipore). For protein extrac-
tion, cells were harvested 48 h after compound-E
treatment and lysed in RIPA-buffer supplemented with
complete protease and phosphatase inhibitors cocktail
(Roche, Penzberg, Germany). The protein extracts were
derived from one well of a six well plate of a single neur-
onal differentiation. Extracts were homogenized andcentrifuged at 10000 × g for 10 min. SDS–polyacrylamide
gel electrophoresis (PAGE) and Western blot analysis of
total proteins were performed [64]. Western blots were in-
cubated with anti-tau monoclonal antibody (1:1000, Cell
Signaling #4019; Frankfurt, Germany), anti p-tau (1:200,
Santa Cruz #sc-32276; Heidelberg, Germany), anti
GSK3A/B (1:1000, Cell Signaling #5676), anti-p-GSK3B
(1:1000, Cell Signaling #5558), anti-b-Tubulin-III (1:1000,
Sigma Aldrich #T8660) anti-Nestin (1:200, Chemicon
#MAB5326), anti-Actin, anti-GAPDH (1:1000, Cell Signal-
ing #5142). Neuroblastoma cell lysates were used as posi-
tive control for p-tau detection (Santa Cruz #SC-2410).
Following incubation with a peroxidase-labelled anti-
rabbit and anti-mouse secondary antibody (1:5000, Dako,
#p0448, #p0447), antigen–antibody complexes were
detected by ECL Western blotting detection reagents
(Peqlab; Erlangen, Germany) for 1 min and exposed to
imaging with the Fusion-FX7 imaging system (Peqlab).
Global gene expression analysis
Total RNA isolated from one well of one reprogramming
or neuronal differentiation experiment was quality-checked
by Nanodrop analysis (Nanodrop; Wilmington, DE, USA)
and 500 ng were used as input. Biotin-labeled cRNA was
produced using a linear amplification kit (Ambion; Austin,
TX, USA). Hybridizations, washing, Cy3-streptavidin
staining and scanning were performed on the Illumina
BeadStation 500 platform (Illumina; San Diego, CA,
USA) according to the manufacturer’s instruction.
cRNA samples were hybridized onto Illumina human-8
BeadChips version 3. The following samples were hy-
bridized in duplicate: H9, NFH-46, NFH-2, AD-iPS5,
AD-iPS26B, AD-iPS5 neurons, iPS26B neurons and H9
neurons. All basic expression data analysis was carried
out using the BeadStudio software 3.0. Raw data were
background-subtracted and normalized using the “rank
invariant” algorithm and then filtered for significant ex-
pression based on negative control beads. Gene expres-
sion results were deposited in the Gene Expression
Omnibus (GEO) repositary website http://www.ncbi.
nlm.nih.gov/geo/; GEO data access number: GSE42492.
Cluster analysis of expression of Alzheimer-associated
genes
Genes associated with Alzheimer in a published genome-
wide association study (GWAS) [34] and known neuronal
marker genes were filtered from the microarray experi-
ments of AD-iPS5 neurons, AD-iPS26 neurons and H9
neurons from one neuronal differentiation experiment
each. Illumina detection p-values were mapped to a binary
scale (0 = not expressed if p-value > 0.05, 1 = expressed
if p-value < = 0.05). These values were clustered via the
R heatmap2 function using Euclidean distance as distance
measure.
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Alzheimer disease, Huntington disease and Parkinson
disease
Functional annotation of significantly regulated genes
from the experiments AD-iPS5 neurons vs. H9 neurons
and AD-iPS26 neurons vs. H9 neurons from one neur-
onal differentiation was performed with the DAVID tool
[65,66]. We focused the analysis on Alzheimer disease-
related KEGG pathways Alzheimer disease, Huntington
disease and Parkinson disease. Only down-regulated
genes (compared to the reference of H9 neurons) were
significantly enriched in these pathways and were there-
fore intersected via Venn diagrams to find overlaps and
differences in the iPS cells concerning these neural dis-
orders. All disjunct sets from this analysis are comprised
in an excel table.Analysis of brain regions associated with regulated
genes
Association of genes with tissues was downloaded from
the Ensembl/Biomart Human genes 75 (GRCh37.p13)
GNF/Atlas organism part annotation data set accounting
for gene expression in organism parts. Only brain re-
gions were used for follow-up processing. These brain
regions were mapped to genes significantly down-regulated
in the AD-iPS neuron experiments which were carried out
once per AD-iPS cell line and were in the KEGG Alzheimer
disease pathway but neither in Huntington disease nor in
Parkinson disease pathways.Cluster analysis of proteasome-specific genes
Genes associated with the proteasome in the literature
and in the gene definition annotation were selected from
the microarray experiments of AD-iPS5 neurons, AD-
iPS26B neurons and H9 neurons from one neuronal
differentiation each. Their Illumina average signal inten-
sities were transformed to a logarithmic scale (log2) and
clustered with the R heatmap2 function using Pearson
correlation as similarity measure.Building of protein association networks
Differentially expressed genes were filtered from the
microarray data by comparing the signal intensities of
AD-iPS neurons and H9 neurons from one neuronal dif-
ferentiation experiment each. Genes with signal intensity
ratios below 0.8 were considered as down-regulated. The
list of official symbols of these genes was used as input
for gene annotation analysis using DAVID Bioinformat-
ics Resources 6.7 [64,65]. Subsequently, a gene list with
the KEGG annotation Alzheimers disease was used as
input for building of the protein association networks
using STRING v9.1 [67,68].Sequence analysis
In this study, we performed a systematic analysis of the
entire coding region including flanking intron sequences
of the genes APP, PSEN1 and PSEN2 by direct sequen-
cing. The target fragments were amplified by polymerase
chain reaction (PCR) using intronic primers designed
from genomic sequence with the Primer 3 software. PCR
products were purified by Exo/SAP digestion (Exonuclease
I; New England; Beverly, MA; shrimp alkaline phosphatase;
Promega, San Diego, CA, USA) and directly sequenced
using ABI-PRISM BigDye® Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems) and the ABI-PRISM
3730 DNA Analyzer, as described by the manufacturer.
Sequences were analyzed using Mutation Surveyor soft-
ware v3.24 (SoftGenetics LLC, State College, PA). The pri-
mer sequences are listed in Additional file 12.
Measurement of telomerase activity
The enzyme activity of telomerase was determined using
the TraPEZE RT Telomerase Detection Kit (Millipore
#S7710) [61].
Karyotype analysis
For detection of possible karyotype abnormalities in two
AD-iPS cell lines, chromosomal analysis after GTG-
banding was performed at the Human Genetic Center,
Berlin, Germany. For each cell line, 25 metaphases were
counted and 6 (NFH-46), 8 (AD-iPS26B) and 10 (AD-iPS5)
karyograms were analyzed [28].
Inhibition of γ-secretase
In order to test the pharmacological response capabilities of




Darmstadt, Germany). Two distinct concentrations were
used: low 10 nM and high 100 nM. The inhibitor was
added to the medium every alternate day for four weeks.
The treated neuronal cells were then harvested in RIPA-
buffer for protein analysis. One neuronal differentiation
and subsequent inhibitor treatment was conduted. Protein
was isolated from one well of the respective experiment.
Detection of HLA haplotype
In order to further characterize the NFH-46 cell line and
its immunogenetic association with AD, genomic DNA
was isolated with the FlexiGene DNA kit (Qiagen; Hilden,
Germany). The purified DNA was then applied to geno-
typing of the HLA–A,B,C and DRB1 genes by PCR with
sequence-specific primers (HLA DNA typing kit; Olerup;
Vienna, Austria) and sequence-specific oligonucleotide
hybridization (LABType HD; BmT, Meerbusch, Germany)
according to the manufacturer’s instructions.
Hossini et al. BMC Genomics  (2015) 16:84 Page 20 of 22Statistical analysis
Data were analyzed using BeadStudio and Microsoft Excel
and are expressed as mean and standard deviation. Data
comparisons between two groups were performed by two-
tailed unpaired Student’s t test, and P-values ≤ 0.05 in
combination with ratios outside the interval [0.8, 1.25]
were considered statistically significant.Additional files
Additional file 1: Sequencing analysis of Alzheimer-related genes
APP, PSEN1, PSEN2. Representative example for DNA sequencing of APP
gene exon 16 of patient NFH-46, lack of mutations Lys670Asn and
Met671Leu (a) and for exon 17 lack of mutation Val717Ile (b).
Additional file 2: Telomerase activity in Alzheimer donor-derived
AD-iPS cells. The telomerase activity was low in the somatic fibroblast
cells NFH-46 from which the two AD-iPS lines AD-iPS5 and AD-iPS26B
were derived. Upon induction of pluripotency, the enzyme was reactivated
in both iPS lines. Human embryonic stem cell lines H1 and H9 and the
telomerase positive control cells (TPC) provided by the kit served as positive
controls. The minus telomerase control (MTC, only CHAPS lysis buffer), no
template control (NTC, only water) and heat inactivated cell extracts served
as negative controls. The standard deviation is indicated by error bars.
Additional file 3: Alkaline phosphatase (AP) staining and DNA
fingerprinting of sporadic AD-iPS cell lines. (a): The two iPS cell lines
derived from the sporadic Alzheimer fibroblasts NFH-46 were positive for
the pluripotency-associated alkaline phosphatase (AP) staining. Morphologies
of both AD-iPSCs are shown in low and high magnification. (b): DNA
fingerprinting confirmed the somatic origin of the two AD-iPS cell lines,
AD-iPS5 and AD-iPS26B, and the lack of cross-contamination with hESC
lines H1 and H9. The AD-iPS cell lines were derived in one reprogramming
experiment.
Additional file 4: Pluripotency-associated genes are expressed in
AD-iPS cells in a similar manner as in ESC line H1. Quantitative real-time
PCR to analyze the expression of the most common pluripotency genes in
the two generated AD-iPS lines (AD-iPS5 and AD-iPS26B) and embryonic
stem cell line H1. Bars indicate the RNA level normalized to β-ACTIN first
and compared to gene expression of NFH-46 (plus standard error of mean
SEM; n = 3). Each AD-iPS cell line was split from one well into the three wells
for expansion before the RNA was isolated. The RNA samples were not
pooled. Both AD iPS cell lines were generated in one reprogramming
experiment.
Additional file 5: Microarray-based gene expression profiling of
AD-iPS cells, control iPS cells and related parental fibroblast cells.
(a): AD-iPS cells (AD-iPS5 and AD-iPS26B), both from one well of one
reprogramming experiment, cluster with control iPS cells (OiPS3 and
OiPS6) and with hESCs (H1 and H9), and are far apart from AD fibroblasts
(NFH-46) and control fibroblasts (NFH-2). (b): Table showing all the
Pearson correlation values r2 between all the single samples analyzed.
For color coding, five distinct degrees of correlation are represented: red
for r2 = 1, orange for 1 < r2 < 0.9, yellow for 0.9 < r2 < 0.8, light yellow for
0.8 < r2 < 0.75, and grey for r2 < 0.75.
Additional file 6: In-vitro differentiation of sporadic AD-iPS cell
lines. Both lines (a) AD-iPS5 and (b) AD-iPS26B could be successfully
differentiated into all three embryonic germ layers in-vitro through an
embryoid body (EB) based differentiation approach. Indicated are the
expression of marker proteins specific for ectoderm, mesoderm, and
endoderm. Scale bars, 100 μm.
Additional file 7: Teratoma formation of sporadic AD-iPS cell lines.
The differentiation potential of the two AD-iPS cell lines was tested
in-vivo with the teratoma formation assay. AD-iPS26B successfully gave
rise to teratoma containing derivatives of all three germ layers. For
AD-iPS5 endodermal cells could not be clearly determined.
Additional file 8: Karyotype of sporadic AD-iPSCs. Karyotyping analysis
of the AD-reprogrammed cells was performed. AD-iPS26B exhibited anormal female karyotype, in a similar fashion to the parental fibroblast cells
NFH-46. AD-iPS5 was found to harbour next to monosomy of the X
chromosome, small supernumerary marker chromosoms (circle).
Additional file 9: Pathways and biological processes significantly
up-regulated in AD-iPSC neuronal cells versus neuronal cells
derived from embryonic stem cells of one neuronal differentiation
experiment each.
Additional file 10: Pathways and biological processes significantly
down-regulated in AD-iPSC neuronal cells versus neuronal cells
derived from embryonic stem cells of one neuronal differentiation
experiment each.
Additional file 11: List of primers used for quantitative real-time
PCR, DNA fingerprinting.
Additional file 12: List of primers used for sequencing of APP,
PSEN1, PSEN2 in sporadic AD-patient derived fibroblasts used to
derive neuronal cells.
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